{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T05:48:02Z","timestamp":1791092882777,"version":"4.1.0"},"reference-count":49,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Cooperative Research and Development Agreement between National Cancer Institute and ImmunityBio","award":["CRADA 2997"],"award-info":[{"award-number":["CRADA 2997"]}]},{"name":"Intramural Research Program, Center for Cancer Research, National Cancer Institue","award":["ZIA BC 010944"],"award-info":[{"award-number":["ZIA BC 010944"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,4,10]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Endogenous retroviruses (ERVs) are remnants of retrovirus germline infections that occurred over the course of evolution and constitute between 5% and 8% of the human genome. While ERVs tend to be epigenetically silenced in normal adult human tissues, they are often overexpressed in carcinomas and may represent novel immunotherapeutic targets. This study characterizes the ERV envelope protein ERVMER34-1 as a target for a therapeutic cancer vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The expression of ERVMER34-1 in multiple healthy adult and cancer tissues was assessed, as was its immunogenicity, to ascertain whether specific T cells could lyse human carcinoma cell lines expressing ERVMER34-1. Furthermore, the ability of a rationally designed ERVMER34-1-targeted therapeutic vaccine to induce tumor clearance in two murine carcinoma models expressing ERVMER34-1 was examined either as a monotherapy or in combination with anti-programmed cell death protein-1\/programmed death-ligand 1 monoclonal antibody (mAb) or the interleukin-15 superagonist N-803.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The ERVMER34-1 protein was shown to be overexpressed in 232\/376 of human carcinomas analyzed while being absent in most healthy adult tissues. High levels of ERVMER34-1 RNA expression associate with decreased survival in uveal melanoma, adenoid cystic, and head and neck carcinomas. ERVMER34-1-specific T cells were detected in peripheral blood mononuclear cells (PBMCs) of patients with cancer but not healthy donors following an overnight stimulation. However, reactive T cells are readily expanded from both healthy donor and patient with cancer PBMCs following a 7-\u2009day in vitro stimulation. Furthermore, ERVMER34-1-specific T cells selectively kill human carcinoma cell lines expressing ERVMER34-1. A novel, rationally designed, therapeutic cancer vaccine targeting ERVMER34-1 mediated tumor control in established syngeneic murine tumors expressing the full-length ERVMER34-1 protein. When combined with checkpoint blockade, the vaccine promoted expansion of neoepitope-reactive T cells whose function was further enhanced when combined with N-803. This expansion of neoepitope-reactive T cells was associated with tumor control.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study reveals the potential of a vaccine that targets the retroviral envelope protein ERVMER34-1 and supports its continued development toward clinical testing as a new class of therapeutic cancer vaccine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-011378","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T22:40:21Z","timestamp":1747176021000},"page":"e011378","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct00001846","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00179309","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01772004","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03050814","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00088413","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02179515","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01519817","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00923741","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00924092","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02840994","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00113984","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-2707","authenticated-orcid":false,"given":"Maria del Mar","family":"Maldonado","sequence":"first","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9334-8177","authenticated-orcid":false,"given":"Maria","family":"Gracia-Hernandez","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3177-8662","authenticated-orcid":false,"given":"Loc Huu","family":"Le","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0095-9767","authenticated-orcid":false,"given":"Masafumi","family":"Iida","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6828-3073","authenticated-orcid":false,"given":"Renee N","family":"Donahue","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0445-4486","authenticated-orcid":false,"given":"Claudia","family":"Palena","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7932-4072","authenticated-orcid":false,"given":"Jeffrey","family":"Schlom","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9730-8209","authenticated-orcid":false,"given":"Duane H","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"2026052723001803000_13.5.e011378.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrg3199"},{"key":"2026052723001803000_13.5.e011378.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0189-2"},{"key":"2026052723001803000_13.5.e011378.3","doi-asserted-by":"publisher","DOI":"10.1038\/35057062"},{"key":"2026052723001803000_13.5.e011378.4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.genet.42.110807.091501"},{"key":"2026052723001803000_13.5.e011378.5","doi-asserted-by":"publisher","DOI":"10.1159\/000084964"},{"key":"2026052723001803000_13.5.e011378.6","doi-asserted-by":"crossref","DOI":"10.1186\/s12977-015-0232-y","article-title":"Classification and characterization of human endogenous retroviruses; mosaic forms are common","volume":"13","author":"Vargiu","year":"2016","journal-title":"Retrovirology (Auckl)"},{"key":"2026052723001803000_13.5.e011378.7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1602336113"},{"key":"2026052723001803000_13.5.e011378.8","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2018.00178","article-title":"HERVs New Role in Cancer: From Accused Perpetrators to Cheerful Protectors","volume":"9","author":"Bannert","year":"2018","journal-title":"Front Microbiol"},{"key":"2026052723001803000_13.5.e011378.9","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.622"},{"key":"2026052723001803000_13.5.e011378.10","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2783"},{"key":"2026052723001803000_13.5.e011378.11","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.4.1640-1648.2004"},{"key":"2026052723001803000_13.5.e011378.12","doi-asserted-by":"publisher","DOI":"10.1038\/2413"},{"key":"2026052723001803000_13.5.e011378.13","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.virol.2010.12.007","article-title":"Dynamic control of endogenous retroviruses during development","volume":"411","author":"Rowe","year":"2011","journal-title":"Virology (Auckl)"},{"key":"2026052723001803000_13.5.e011378.14","doi-asserted-by":"publisher","DOI":"10.1101\/gr.121749.111"},{"key":"2026052723001803000_13.5.e011378.15","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btn243"},{"key":"2026052723001803000_13.5.e011378.16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00646-08"},{"key":"2026052723001803000_13.5.e011378.17","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-8-S2-S11","article-title":"Methods for estimating human endogenous retrovirus activities from EST databases","volume":"8 Suppl 2","author":"Oja","year":"2007","journal-title":"BMC Bioinformatics"},{"key":"2026052723001803000_13.5.e011378.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040194","article-title":"Microarray-based sketches of the HERV transcriptome landscape","volume":"7","author":"P\u00e9rot","year":"2012","journal-title":"PLoS One"},{"key":"2026052723001803000_13.5.e011378.19","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019505","article-title":"Epigenetic Determinants of Cancer","volume":"8","author":"Baylin","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026052723001803000_13.5.e011378.20","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24902"},{"key":"2026052723001803000_13.5.e011378.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.12.033"},{"key":"2026052723001803000_13.5.e011378.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6838"},{"key":"2026052723001803000_13.5.e011378.23","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0388"},{"key":"2026052723001803000_13.5.e011378.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-3139"},{"key":"2026052723001803000_13.5.e011378.25","first-page":"5510","article-title":"A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes","volume":"62","author":"Schiavetti","year":"2002","journal-title":"Cancer Res"},{"key":"2026052723001803000_13.5.e011378.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1183-3"},{"key":"2026052723001803000_13.5.e011378.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19464-8","article-title":"Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers","volume":"11","author":"Saini","year":"2020","journal-title":"Nat Commun"},{"key":"2026052723001803000_13.5.e011378.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072756","article-title":"Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system","volume":"8","author":"Kraus","year":"2013","journal-title":"PLoS ONE"},{"key":"2026052723001803000_13.5.e011378.29","doi-asserted-by":"crossref","DOI":"10.1186\/1743-422X-11-58","article-title":"Vaccination directed against the human endogenous retrovirus-K (HERV-K) gag protein slows HERV-K gag expressing cell growth in a murine model system","volume":"11","author":"Kraus","year":"2014","journal-title":"Virol J"},{"key":"2026052723001803000_13.5.e011378.30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200079"},{"key":"2026052723001803000_13.5.e011378.31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26680"},{"key":"2026052723001803000_13.5.e011378.32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1702204114"},{"key":"2026052723001803000_13.5.e011378.33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/1878-0261.13069","article-title":"Therapeutic potential of the human endogenous retroviral envelope protein HEMO: a pan-cancer analysis","volume":"16","author":"Kasperek","year":"2022","journal-title":"Mol Oncol"},{"key":"2026052723001803000_13.5.e011378.34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0483"},{"key":"2026052723001803000_13.5.e011378.35","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(01)00107-8"},{"key":"2026052723001803000_13.5.e011378.36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol"},{"key":"2026052723001803000_13.5.e011378.37","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200167","article-title":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","volume":"2","author":"Chamie","year":"2023","journal-title":"NEJM Evid"},{"key":"2026052723001803000_13.5.e011378.38","unstructured":"Childs RW . HERV-E TCR transduced autologous T cells in people with metastatic clear cell renal cell carcinoma. ClinicalTrialsgov 2018."},{"key":"2026052723001803000_13.5.e011378.39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI34409C1"},{"key":"2026052723001803000_13.5.e011378.40","doi-asserted-by":"crossref","first-page":"368","DOI":"10.5483\/BMBRep.2021.54.7.246","article-title":"Expression profiles of human endogenous retrovirus (HERV)-K and HERV-R Env proteins in various cancers","volume":"54","author":"Ko","year":"2021","journal-title":"BMB Rep"},{"key":"2026052723001803000_13.5.e011378.41","doi-asserted-by":"crossref","first-page":"31344","DOI":"10.18632\/oncotarget.5181","article-title":"The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic","volume":"6","author":"Gabitzsch","year":"2015","journal-title":"Oncotarget"},{"key":"2026052723001803000_13.5.e011378.42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1998.tb09119.x"},{"key":"2026052723001803000_13.5.e011378.43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/1040-8428(93)90009-S","article-title":"Immunosuppression by retroviral-envelope-related proteins, and their role in non-retroviral human disease","volume":"14","author":"Oostendorp","year":"1993","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026052723001803000_13.5.e011378.44","doi-asserted-by":"publisher","DOI":"10.1126\/science.2996136"},{"key":"2026052723001803000_13.5.e011378.45","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-82-10-2515"},{"key":"2026052723001803000_13.5.e011378.46","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1128\/jvi.63.8.3257-3260.1989","article-title":"Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1","volume":"63","author":"Ruegg","year":"1989","journal-title":"J Virol"},{"key":"2026052723001803000_13.5.e011378.47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.25.14920"},{"key":"2026052723001803000_13.5.e011378.48","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-15-0064"},{"key":"2026052723001803000_13.5.e011378.49","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011378","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:00:28Z","timestamp":1779948028000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/jitc-2024-011378"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011378","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}